Filing Flows › Rigel Pharmaceuticals (RIGL) › Q3 2026
Rigel Pharmaceuticals (RIGL) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 5, 2026
Rigel Pharmaceuticals (RIGL) reported revenue of $80.9M for the third quarter 2026 (Q3 2026), +16% from a year earlier and +3% from the quarter before. Operating margin was 21.1%, net earnings $13.2M (16.3% of revenue).
Rigel Pharmaceuticals, Q3 2026: revenue $80.9M (+16% year over year), operating margin 21.1%, net earnings $13.2M, operating cash flow $34.6M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $80.9M | +3% | +16% |
| Operating profit | $17.1M | -27% | -40% |
| Net earnings | $13.2M | -24% | -53% |
| Operating cash flow | $34.6M | +13% | +44% |
What changed
Revenue was $80.9M in Q3 2026, up 16% year over year and up 3% from the previous quarter. Product sales, net was the largest line at 89% of revenue. Product sales, net added $8.2M year over year (up 13%), 72% of the total change.
Operating profit was $17.1M, a 21.1% margin (down 19.8 points year over year). Operating profit fell $11.3M even though revenue rose $11.4M versus Q3 2025, so costs grew faster than sales. Total costs grew 55% against revenue growth of 16%. The fastest-growing cost line was Research & development (+148%). Net earnings were $13.2M, down 53% year over year. The effective tax rate was 24.3%.
Operating cash flow was $34.6M (up 44% year over year), 262% of net earnings. Non-cash charges added back $1.8M of depreciation and amortization and $4.9M of share-based compensation. Working capital and other items added $14.7M.
Questions
What was Rigel Pharmaceuticals' revenue in the third quarter 2026?
Rigel Pharmaceuticals (RIGL) reported revenue of $80.9M for the third quarter 2026 (Q3 2026), +16% from a year earlier and +3% from the quarter before.
Was Rigel Pharmaceuticals profitable in the third quarter 2026?
Operating profit was $17.1M (21.1% of revenue) and net earnings $13.2M.